메뉴 건너뛰기




Volumn 12, Issue 7, 2014, Pages 793-807

Update on antiretroviral treatment during primary HIV infection

Author keywords

Acute retroviral syndrome; Antiretroviral treatment; Eradication; Fiebig phases; Functional cure; HIV guidelines; HIV infection; Primary HIV infection; Therapeutic vaccines; Transmitted drug resistance

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

EID: 84902480343     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.913981     Document Type: Review
Times cited : (22)

References (121)
  • 1
    • 0033758427 scopus 로고    scopus 로고
    • Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group
    • Lindback S, Karlsson AC, Mittler J, et al. Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS 2000;14(15):2283-91
    • (2000) AIDS , vol.14 , Issue.15 , pp. 2283-2291
    • Lindback, S.1    Karlsson, A.C.2    Mittler, J.3
  • 2
    • 11344286574 scopus 로고    scopus 로고
    • Advances in the diagnosis and treatment of acute human immunodeficiency virus type 1 (HIV-1) infection
    • Miro JM, Sued O, Plana M, et al. [Advances in the diagnosis and treatment of acute human immunodeficiency virus type 1 (HIV-1) infection]. Enferm Infecc Microbiol Clin 2004;22(10):643-59
    • (2004) Enferm Infecc Microbiol Clin , vol.22 , Issue.10 , pp. 643-659
    • Miro, J.M.1    Sued, O.2    Plana, M.3
  • 4
    • 2142810214 scopus 로고    scopus 로고
    • Acute HIV revisited: New opportunities for treatment and prevention
    • Pilcher CD, Eron JJ Jr, Galvin S, et al. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest 2004;113(7):937-45
    • (2004) J Clin Invest , vol.113 , Issue.7 , pp. 937-945
    • Pilcher, C.D.1    Eron Jr., J.J.2    Galvin, S.3
  • 6
    • 84867745551 scopus 로고    scopus 로고
    • Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections
    • Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. AIDS 2012;26(16):2079-86
    • (2012) AIDS , vol.26 , Issue.16 , pp. 2079-2086
    • Ambrosioni, J.1    Junier, T.2    Delhumeau, C.3
  • 7
    • 80051633217 scopus 로고    scopus 로고
    • Prevention of HIV-1 infection with early antiretroviral therapy
    • Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365(6):493-505
    • (2011) N Engl J Med , vol.365 , Issue.6 , pp. 493-505
    • Cohen, M.S.1    Chen, Y.Q.2    McCauley, M.3
  • 9
    • 67650651959 scopus 로고    scopus 로고
    • Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: A cohort of high-risk men who have sex with men
    • Fox J, White PJ, Macdonald N, et al. Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med 2009; 10(7):432-8
    • (2009) HIV Med , vol.10 , Issue.7 , pp. 432-438
    • Fox, J.1    White, P.J.2    Macdonald, N.3
  • 10
    • 77951879238 scopus 로고    scopus 로고
    • HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men
    • Rieder P, Joos B, von Wyl V, et al. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS 2010;24(8):1177-83
    • (2010) AIDS , vol.24 , Issue.8 , pp. 1177-1183
    • Rieder, P.1    Joos, B.2    Von Wyl, V.3
  • 11
    • 77953916829 scopus 로고    scopus 로고
    • Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection
    • Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010;24(10): 1598-601
    • (2010) AIDS , vol.24 , Issue.10 , pp. 1598-1601
    • Hocqueloux, L.1    Prazuck, T.2    Avettand-Fenoel, V.3
  • 12
    • 84876411341 scopus 로고    scopus 로고
    • Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts
    • Hocqueloux L, Avettand-Fenoel V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013; 68(5):1169-78
    • (2013) J Antimicrob Chemother , vol.68 , Issue.5 , pp. 1169-1178
    • Hocqueloux, L.1    Avettand-Fenoel, V.2    Jacquot, S.3
  • 13
    • 0035862330 scopus 로고    scopus 로고
    • Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
    • Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001;193(2):169-80
    • (2001) J Exp Med , vol.193 , Issue.2 , pp. 169-180
    • Altfeld, M.1    Rosenberg, E.S.2    Shankarappa, R.3
  • 14
    • 0034743924 scopus 로고    scopus 로고
    • Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection
    • Cohen DE, Walker BD. Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection. Clin Infect Dis 2001;32(12):1756-68
    • (2001) Clin Infect Dis , vol.32 , Issue.12 , pp. 1756-1768
    • Cohen, D.E.1    Walker, B.D.2
  • 15
    • 0035822949 scopus 로고    scopus 로고
    • Distribution of functional HIV-specific CD8 T lymphocytes between blood and secondary lymphoid organs after 8-18 months of antiretroviral therapy in acutely infected patients
    • Oxenius A, Yerly S, Ramirez E, et al. Distribution of functional HIV-specific CD8 T lymphocytes between blood and secondary lymphoid organs after 8-18 months of antiretroviral therapy in acutely infected patients. AIDS 2001; 15(13):1653-6
    • (2001) AIDS , vol.15 , Issue.13 , pp. 1653-1656
    • Oxenius, A.1    Yerly, S.2    Ramirez, E.3
  • 16
    • 0035660401 scopus 로고    scopus 로고
    • Variable fate of virus-specific CD4(+) T cells during primary HIV-1 infection
    • Oxenius A, Fidler S, Brady M, et al. Variable fate of virus-specific CD4(+) T cells during primary HIV-1 infection. Eur J Immunol 2001;31(12):3782-8
    • (2001) Eur J Immunol , vol.31 , Issue.12 , pp. 3782-3788
    • Oxenius, A.1    Fidler, S.2    Brady, M.3
  • 17
    • 0034727073 scopus 로고    scopus 로고
    • Immune control of HIV-1 after early treatment of acute infection
    • Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407(6803):523-6
    • (2000) Nature , vol.407 , Issue.6803 , pp. 523-526
    • Rosenberg, E.S.1    Altfeld, M.2    Poon, S.H.3
  • 18
    • 69449099364 scopus 로고    scopus 로고
    • Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells
    • Lecuroux C, Girault I, Boutboul F, et al. Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells. AIDS 2009;23(13):1649-58
    • (2009) AIDS , vol.23 , Issue.13 , pp. 1649-1658
    • Lecuroux, C.1    Girault, I.2    Boutboul, F.3
  • 19
    • 72949117233 scopus 로고    scopus 로고
    • The immune response during acute HIV-1 infection: Clues for vaccine development
    • McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10(1):11-23
    • (2010) Nat Rev Immunol , vol.10 , Issue.1 , pp. 11-23
    • McMichael, A.J.1    Borrow, P.2    Tomaras, G.D.3
  • 20
    • 33845904393 scopus 로고    scopus 로고
    • Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection
    • Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 2006;3(12):e484
    • (2006) PLoS Med , vol.3 , Issue.12
    • Mehandru, S.1    Poles, M.A.2    Tenner-Racz, K.3
  • 21
    • 4644289983 scopus 로고    scopus 로고
    • Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract
    • Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200(6):761-70
    • (2004) J Exp Med , vol.200 , Issue.6 , pp. 761-770
    • Mehandru, S.1    Poles, M.A.2    Tenner-Racz, K.3
  • 23
    • 33846932807 scopus 로고    scopus 로고
    • Spanish cohort of naive HIV-infected patients (CoRIS): Rationale, organization and initial results
    • Caro-Murillo AM, Castilla J, Perez-Hoyos S, et al. [Spanish cohort of naive HIV-infected patients (CoRIS): rationale, organization and initial results]. Enferm Infecc Microbiol Clin 2007;25(1):23-31
    • (2007) Enferm Infecc Microbiol Clin , vol.25 , Issue.1 , pp. 23-31
    • Caro-Murillo, A.M.1    Castilla, J.2    Perez-Hoyos, S.3
  • 24
    • 77957155418 scopus 로고    scopus 로고
    • Population-based HIV-1 incidence in France, 2003-08: A modelling analysis
    • Le VS, Le SY, Barin F, et al. Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis 2010;10(10):682-7
    • (2010) Lancet Infect Dis , vol.10 , Issue.10 , pp. 682-687
    • Le, V.S.1    Le, S.Y.2    Barin, F.3
  • 25
    • 65649107322 scopus 로고    scopus 로고
    • Recently acquired HIV infection in Spain (2003-2005): Introduction of the serological testing algorithm for recent HIV seroconversion
    • Romero A, Gonzalez V, Granell M, et al. Recently acquired HIV infection in Spain (2003-2005): introduction of the serological testing algorithm for recent HIV seroconversion. Sex Transm Infect 2009; 85(2):106-10
    • (2009) Sex Transm Infect , vol.85 , Issue.2 , pp. 106-110
    • Romero, A.1    Gonzalez, V.2    Granell, M.3
  • 26
    • 84870555430 scopus 로고    scopus 로고
    • Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08)
    • Romero A, Gonzalez V, Esteve A, et al. Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08). Eur J Public Health 2012; 22(6):802-8
    • (2012) Eur J Public Health , vol.22 , Issue.6 , pp. 802-808
    • Romero, A.1    Gonzalez, V.2    Esteve, A.3
  • 27
    • 0033767914 scopus 로고    scopus 로고
    • Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group
    • Lindback S, Thorstensson R, Karlsson AC, et al. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS 2000;14(15): 2333-9
    • (2000) AIDS , vol.14 , Issue.15 , pp. 2333-2339
    • Lindback, S.1    Thorstensson, R.2    Karlsson, A.C.3
  • 28
    • 84882579669 scopus 로고    scopus 로고
    • Tissue dendritic cells as portals for HIV entry
    • Harman AN, Kim M, Nasr N, et al. Tissue dendritic cells as portals for HIV entry. Rev Med Virol 2013;23(5):319-33
    • (2013) Rev Med Virol , vol.23 , Issue.5 , pp. 319-333
    • Harman, A.N.1    Kim, M.2    Nasr, N.3
  • 29
    • 77954349748 scopus 로고    scopus 로고
    • Determinants of HIV-1 transmission in men who have sex with men: A combined clinical, epidemiological and phylogenetic approach
    • Fisher M, Pao D, Brown AE, et al. Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS 2010;24(11):1739-47
    • (2010) AIDS , vol.24 , Issue.11 , pp. 1739-1747
    • Fisher, M.1    Pao, D.2    Brown, A.E.3
  • 30
    • 77956638123 scopus 로고    scopus 로고
    • Longitudinal phylogenetic surveillance identifies distinct patterns of cluster dynamics
    • Ragonnet-Cronin M, Ofner-Agostini M, Merks H, et al. Longitudinal phylogenetic surveillance identifies distinct patterns of cluster dynamics. J Acquir Immune Defic Syndr 2010;55(1):102-8
    • (2010) J Acquir Immune Defic Syndr , vol.55 , Issue.1 , pp. 102-108
    • Ragonnet-Cronin, M.1    Ofner-Agostini, M.2    Merks, H.3
  • 31
    • 68449091365 scopus 로고    scopus 로고
    • The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection
    • Yerly S, Junier T, Gayet-Ageron A, et al. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 2009;23(11): 1415-23
    • (2009) AIDS , vol.23 , Issue.11 , pp. 1415-1423
    • Yerly, S.1    Junier, T.2    Gayet-Ageron, A.3
  • 32
    • 34447554516 scopus 로고    scopus 로고
    • Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection
    • Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 2007;59(6):1047-56
    • (2007) J Antimicrob Chemother , vol.59 , Issue.6 , pp. 1047-1056
    • Booth, C.L.1    Geretti, A.M.2
  • 33
    • 1242343608 scopus 로고    scopus 로고
    • Epidemiological aspects of transmitted HIV drug resistance
    • Girardi E. Epidemiological aspects of transmitted HIV drug resistance. Scand J Infect Dis Suppl 2003;106:17-20
    • (2003) Scand J Infect Dis Suppl , vol.106 , pp. 17-20
    • Girardi, E.1
  • 34
    • 77957607422 scopus 로고    scopus 로고
    • Epidemiology of drug-resistant HIV-1 transmission in naive patients in Spain
    • Yebra G, Holguin A. [Epidemiology of drug-resistant HIV-1 transmission in naive patients in Spain]. Med Clin (Barc) 2010; 135(12):561-7
    • (2010) Med Clin (Barc) , vol.135 , Issue.12 , pp. 561-567
    • Yebra, G.1    Holguin, A.2
  • 35
    • 27444439834 scopus 로고    scopus 로고
    • Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain
    • de Mendoza C, Rodriguez C, Colomina J, et al. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis 2005; 41(9):1350-4
    • (2005) Clin Infect Dis , vol.41 , Issue.9 , pp. 1350-1354
    • De Mendoza, C.1    Rodriguez, C.2    Colomina, J.3
  • 36
    • 20244384565 scopus 로고    scopus 로고
    • French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002
    • Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005;38(5):545-52
    • (2005) J Acquir Immune Defic Syndr , vol.38 , Issue.5 , pp. 545-552
    • Descamps, D.1    Chaix, M.L.2    Andre, P.3
  • 37
    • 2542427688 scopus 로고    scopus 로고
    • Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001
    • Violin M, Velleca R, Cozzi-Lepri A, et al. Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001. J Acquir Immune Defic Syndr 2004;36(2):761-4
    • (2004) J Acquir Immune Defic Syndr , vol.36 , Issue.2 , pp. 761-764
    • Violin, M.1    Velleca, R.2    Cozzi-Lepri, A.3
  • 38
    • 84858128537 scopus 로고    scopus 로고
    • Documented prevalence of HIV type 1 antiretroviral transmitted drug resistance in Ireland from 2004 to 2008
    • De Gascun CF, Waters A, Regan C, et al. Documented prevalence of HIV type 1 antiretroviral transmitted drug resistance in Ireland from 2004 to 2008. AIDS Res Hum Retroviruses 2012;28(3): 276-81
    • (2012) AIDS Res Hum Retroviruses , vol.28 , Issue.3 , pp. 276-281
    • De Gascun, C.F.1    Waters, A.2    Regan, C.3
  • 39
    • 84867698975 scopus 로고    scopus 로고
    • Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class
    • Monge S, Guillot V, Alvarez M, et al. Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. Clin Microbiol Infect 2012; 18(11):E485-90
    • (2012) Clin Microbiol Infect , vol.18 , Issue.11
    • Monge, S.1    Guillot, V.2    Alvarez, M.3
  • 40
    • 84886246087 scopus 로고    scopus 로고
    • National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011
    • Descamps D, Assoumou L, Chaix ML, et al. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. J Antimicrob Chemother 2013; 68(11):2626-31
    • (2013) J Antimicrob Chemother , vol.68 , Issue.11 , pp. 2626-2631
    • Descamps, D.1    Assoumou, L.2    Chaix, M.L.3
  • 41
    • 84858680178 scopus 로고    scopus 로고
    • Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010
    • Karlsson A, Bjorkman P, Bratt G, et al. Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One 2012;7(3):e33484
    • (2012) PLoS One , vol.7 , Issue.3
    • Karlsson, A.1    Bjorkman, P.2    Bratt, G.3
  • 42
    • 70449723682 scopus 로고    scopus 로고
    • Transmission of drug-resistant HIV-1 is stabilizing in Europe
    • Vercauteren J, Wensing AM, Van de Vijver DA, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009;200(10):1503-8
    • (2009) J Infect Dis , vol.200 , Issue.10 , pp. 1503-1508
    • Vercauteren, J.1    Wensing, A.M.2    Van De Vijver, D.A.3
  • 43
    • 24644472997 scopus 로고    scopus 로고
    • Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management
    • Wensing AM, Van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192(6):958-66
    • (2005) J Infect Dis , vol.192 , Issue.6 , pp. 958-966
    • Wensing, A.M.1    Van De Vijver, D.A.2    Angarano, G.3
  • 44
    • 79955477986 scopus 로고    scopus 로고
    • Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study
    • Wittkop L, Gunthard HF, de WF, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011;11(5):363-71
    • (2011) Lancet Infect Dis , vol.11 , Issue.5 , pp. 363-371
    • Wittkop, L.1    Gunthard, H.F.2    De, W.F.3
  • 45
    • 33846440130 scopus 로고    scopus 로고
    • Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection
    • Smith D, Moini N, Pesano R, et al. Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin Infect Dis 2007;44(3):456-8
    • (2007) Clin Infect Dis , vol.44 , Issue.3 , pp. 456-458
    • Smith, D.1    Moini, N.2    Pesano, R.3
  • 46
    • 2942529150 scopus 로고    scopus 로고
    • The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities
    • Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189(12):2174-80
    • (2004) J Infect Dis , vol.189 , Issue.12 , pp. 2174-2180
    • Weinstock, H.S.1    Zaidi, I.2    Heneine, W.3
  • 47
    • 0037043652 scopus 로고    scopus 로고
    • Antiretroviral-drug resistance among patients recently infected with HIV
    • Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347(6):385-94
    • (2002) N Engl J Med , vol.347 , Issue.6 , pp. 385-394
    • Little, S.J.1    Holte, S.2    Routy, J.P.3
  • 48
    • 77951877448 scopus 로고    scopus 로고
    • Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U. S.-2006
    • Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010;24(8):1203-12
    • (2010) AIDS , vol.24 , Issue.8 , pp. 1203-1212
    • Wheeler, W.H.1    Ziebell, R.A.2    Zabina, H.3
  • 50
    • 79959241249 scopus 로고    scopus 로고
    • Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe
    • Tshabalala M, Manasa J, Zijenah LS, et al. Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe. PLoS One 2011; 6(6):e21241
    • (2011) PLoS One , vol.6 , Issue.6
    • Tshabalala, M.1    Manasa, J.2    Zijenah, L.S.3
  • 51
    • 84865607405 scopus 로고    scopus 로고
    • HIV-1 genetic diversity and transmitted drug resistance mutations among patients from the North, Central and South regions of Angola
    • Afonso JM, Bello G, Guimaraes ML, et al. HIV-1 genetic diversity and transmitted drug resistance mutations among patients from the North, Central and South regions of Angola. PLoS One 2012;7(8):e42996
    • (2012) PLoS One , vol.7 , Issue.8
    • Afonso, J.M.1    Bello, G.2    Guimaraes, M.L.3
  • 52
    • 80053293363 scopus 로고    scopus 로고
    • HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: A multicentre observational study
    • Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011;11(10):750-9
    • (2011) Lancet Infect Dis , vol.11 , Issue.10 , pp. 750-759
    • Hamers, R.L.1    Wallis, C.L.2    Kityo, C.3
  • 53
    • 84874249113 scopus 로고    scopus 로고
    • WHO. WHO HIV Drug Resistance Report 2012. Available from: www.who.int/mediacentre/news/notes/2012/hiv-drug-resistance-20120718/en/index. html
    • WHO HIV Drug Resistance Report 2012
  • 54
    • 84871921929 scopus 로고    scopus 로고
    • Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa
    • Hamers RL, Sigaloff KC, Kityo C, et al. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS 2013;8(1):19-26
    • (2013) Curr Opin HIV AIDS , vol.8 , Issue.1 , pp. 19-26
    • Hamers, R.L.1    Sigaloff, K.C.2    Kityo, C.3
  • 55
    • 84873376567 scopus 로고    scopus 로고
    • Transmitted drug resistance among people living with HIV/Aids at Major Cities of Sao Paulo State, Brazil
    • Ferreira JL, Rodrigues R, Lanca AM, et al. Transmitted Drug Resistance among People Living with HIV/Aids at Major Cities of Sao Paulo State, Brazil. Adv Virol 2013;2013:878237
    • (2013) Adv Virol , vol.2013 , pp. 878237
    • Ferreira, J.L.1    Rodrigues, R.2    Lanca, A.M.3
  • 56
    • 84858771311 scopus 로고    scopus 로고
    • National prevalence and trends of HIV transmitted drug resistance in Mexico
    • Ávila-Ríos S, Garcia-Morales C, Garrido-Rodriguez D, et al. National prevalence and trends of HIV transmitted drug resistance in Mexico. PLoS One 2011; 6(11):e27812
    • (2011) PLoS One , vol.6 , Issue.11
    • Ávila-Ríos, S.1    Garcia-Morales, C.2    Garrido-Rodriguez, D.3
  • 57
    • 84876065066 scopus 로고    scopus 로고
    • The emergence of HIV-1 primary drug resistance genotypes among treatment-naive men who have sex with men in high-prevalence areas in China
    • Yang J, Xing H, Niu J, et al. The emergence of HIV-1 primary drug resistance genotypes among treatment-naive men who have sex with men in high-prevalence areas in China. Arch Virol 2013;158(4):839-44
    • (2013) Arch Virol , vol.158 , Issue.4 , pp. 839-844
    • Yang, J.1    Xing, H.2    Niu, J.3
  • 58
    • 84857942730 scopus 로고    scopus 로고
    • Emergence of HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand
    • Sungkanuparph S, Sukasem C, Kiertiburanakul S, et al. Emergence of HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand. J Int AIDS Soc 2012; 15(1):12
    • (2012) J Int AIDS Soc , vol.15 , Issue.1 , pp. 12
    • Sungkanuparph, S.1    Sukasem, C.2    Kiertiburanakul, S.3
  • 59
    • 77956924027 scopus 로고    scopus 로고
    • Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: Nationwide surveillance from 2003 to 2008 in Japan
    • Hattori J, Shiino T, Gatanaga H, et al. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res 2010;88(1):72-9
    • (2010) Antiviral Res , vol.88 , Issue.1 , pp. 72-79
    • Hattori, J.1    Shiino, T.2    Gatanaga, H.3
  • 60
    • 84859618898 scopus 로고    scopus 로고
    • Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan
    • Lai CC, Hung CC, Chen MY, et al. Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. J Antimicrob Chemother 2012;67(5):1254-60
    • (2012) J Antimicrob Chemother , vol.67 , Issue.5 , pp. 1254-1260
    • Lai, C.C.1    Hung, C.C.2    Chen, M.Y.3
  • 61
    • 0041828179 scopus 로고    scopus 로고
    • Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection
    • Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003;17(13): 1871-9
    • (2003) AIDS , vol.17 , Issue.13 , pp. 1871-1879
    • Fiebig, E.W.1    Wright, D.J.2    Rawal, B.D.3
  • 62
    • 84878214420 scopus 로고    scopus 로고
    • A novel acute HIV infection staging system based on 4th generation immunoassay
    • Ananworanich J, Fletcher JL, Pinyakorn S, et al. A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology 2013;10:56
    • (2013) Retrovirology , vol.10 , pp. 56
    • Ananworanich, J.1    Fletcher, J.L.2    Pinyakorn, S.3
  • 63
    • 33846034454 scopus 로고    scopus 로고
    • Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection
    • Mehandru S, Poles MA, Tenner-Racz K, et al. Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol 2007;81(2): 599-612
    • (2007) J Virol , vol.81 , Issue.2 , pp. 599-612
    • Mehandru, S.1    Poles, M.A.2    Tenner-Racz, K.3
  • 64
    • 4644289983 scopus 로고    scopus 로고
    • Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract
    • Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200(6):761-70
    • (2004) J Exp Med , vol.200 , Issue.6 , pp. 761-770
    • Mehandru, S.1    Poles, M.A.2    Tenner-Racz, K.3
  • 65
    • 33845904393 scopus 로고    scopus 로고
    • Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection
    • Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 2006;3(12):e484
    • (2006) PLoS Med , vol.3 , Issue.12
    • Mehandru, S.1    Poles, M.A.2    Tenner-Racz, K.3
  • 66
    • 35748939690 scopus 로고    scopus 로고
    • HIV disease progression: Immune activation, microbes, and a leaky gut
    • Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med 2007;15(4):114-17
    • (2007) Top HIV Med , vol.15 , Issue.4 , pp. 114-117
    • Douek, D.1
  • 67
    • 84897983332 scopus 로고    scopus 로고
    • Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression
    • Hamlyn E, Fidler S, Stohr W, et al. Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression. AIDS 2013; 28(6):869-74
    • (2013) AIDS , vol.28 , Issue.6 , pp. 869-874
    • Hamlyn, E.1    Fidler, S.2    Stohr, W.3
  • 68
    • 84873481136 scopus 로고    scopus 로고
    • Soluble biomarkers of HIV transmission, disease progression and comorbidities
    • Leeansyah E, Malone DF, Anthony DD, Sandberg JK. Soluble biomarkers of HIV transmission, disease progression and comorbidities. Curr Opin HIV AIDS 2013; 8(2):117-24
    • (2013) Curr Opin HIV AIDS , vol.8 , Issue.2 , pp. 117-124
    • Leeansyah, E.1    Malone, D.F.2    Anthony, D.D.3    Sandberg, J.K.4
  • 69
    • 33646085538 scopus 로고    scopus 로고
    • Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women
    • Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006;42(9):1333-9
    • (2006) Clin Infect Dis , vol.42 , Issue.9 , pp. 1333-1339
    • Lavreys, L.1    Baeten, J.M.2    Chohan, V.3
  • 70
    • 81155158293 scopus 로고    scopus 로고
    • Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters
    • Socias ME, Sued O, Laufer N, et al. Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. J Int AIDS Soc 2011;14:40
    • (2011) J Int AIDS Soc , vol.14 , pp. 40
    • Socias, M.E.1    Sued, O.2    Laufer, N.3
  • 71
    • 33144485618 scopus 로고    scopus 로고
    • CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients
    • Goujard C, Bonarek M, Meyer L, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006;42(5):709-15
    • (2006) Clin Infect Dis , vol.42 , Issue.5 , pp. 709-715
    • Goujard, C.1    Bonarek, M.2    Meyer, L.3
  • 72
    • 84902490773 scopus 로고    scopus 로고
    • Host-Virus interactions in HIV-1 rapid disease progression
    • Barcelona, Spain, 7-10 October 2013 (Abstract S05-02)
    • Martinez-Picado J. Host-Virus interactions in HIV-1 rapid disease progression. AIDS Vaccine 2013; Barcelona, Spain, 7-10 October 2013 (Abstract S05-02)
    • (2013) AIDS Vaccine
    • Martinez-Picado, J.1
  • 73
    • 67249147641 scopus 로고    scopus 로고
    • High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: The French ANRS CO06 PRIMO Cohort Study
    • Frange P, Galimand J, Goujard C, et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother 2009; 64(1):135-41
    • (2009) J Antimicrob Chemother , vol.64 , Issue.1 , pp. 135-141
    • Frange, P.1    Galimand, J.2    Goujard, C.3
  • 74
    • 84876344448 scopus 로고    scopus 로고
    • Prevalence of CXCR4-tropic viruses in clustered transmission chains at the time of primary HIV-1 infection
    • Frange P, Meyer L, Ghosn J, et al. Prevalence of CXCR4-tropic viruses in clustered transmission chains at the time of primary HIV-1 infection. Clin Microbiol Infect 2013;19(5):E252-5
    • (2013) Clin Microbiol Infect , vol.19 , Issue.5
    • Frange, P.1    Meyer, L.2    Ghosn, J.3
  • 75
    • 84874779902 scopus 로고    scopus 로고
    • Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy
    • Chaix ML, Seng R, Frange P, et al. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. Clin Infect Dis 2013; 56(6):880-7
    • (2013) Clin Infect Dis , vol.56 , Issue.6 , pp. 880-887
    • Chaix, M.L.1    Seng, R.2    Frange, P.3
  • 77
    • 70049106041 scopus 로고    scopus 로고
    • Spontaneous control of viral replication during primary HIV infection: When is "HIV controller" status established?
    • Goujard C, Chaix ML, Lambotte O, et al. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis 2009;49(6):982-6
    • (2009) Clin Infect Dis , vol.49 , Issue.6 , pp. 982-986
    • Goujard, C.1    Chaix, M.L.2    Lambotte, O.3
  • 78
    • 84872452352 scopus 로고    scopus 로고
    • Short-course antiretroviral therapy in primary HIV infection
    • Fidler S, Porter K, Ewings F, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368(3):207-17
    • (2013) N Engl J Med , vol.368 , Issue.3 , pp. 207-217
    • Fidler, S.1    Porter, K.2    Ewings, F.3
  • 79
    • 33748433647 scopus 로고    scopus 로고
    • Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection
    • Streeck H, Jessen H, Alter G, et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 2006;194(6):734-9
    • (2006) J Infect Dis , vol.194 , Issue.6 , pp. 734-739
    • Streeck, H.1    Jessen, H.2    Alter, G.3
  • 80
    • 0036720475 scopus 로고    scopus 로고
    • Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination
    • Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002;186(5): 634-43
    • (2002) J Infect Dis , vol.186 , Issue.5 , pp. 634-643
    • Markowitz, M.1    Jin, X.2    Hurley, A.3
  • 81
    • 19944428989 scopus 로고    scopus 로고
    • Does transient HAART during primary HIV-1 infection lower the virological set-point?
    • Desquilbet L, Goujard C, Rouzioux C, et al. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004;18(18): 2361-9
    • (2004) AIDS , vol.18 , Issue.18 , pp. 2361-2369
    • Desquilbet, L.1    Goujard, C.2    Rouzioux, C.3
  • 82
    • 33748428894 scopus 로고    scopus 로고
    • A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection
    • Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006;194(6):725-33
    • (2006) J Infect Dis , vol.194 , Issue.6 , pp. 725-733
    • Hecht, F.M.1    Wang, L.2    Collier, A.3
  • 83
    • 77951798589 scopus 로고    scopus 로고
    • Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection
    • Steingrover R, Garcia EF, van Valkengoed IG, et al. Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. AIDS Res Hum Retroviruses 2010;26(4):379-87
    • (2010) AIDS Res Hum Retroviruses , vol.26 , Issue.4 , pp. 379-387
    • Steingrover, R.1    Garcia, E.F.2    Van Valkengoed, I.G.3
  • 84
    • 70149102076 scopus 로고    scopus 로고
    • Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort
    • Koegl C, Wolf E, Hanhoff N, et al. Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res 2009;14(7):277-83
    • (2009) Eur J Med Res , vol.14 , Issue.7 , pp. 277-283
    • Koegl, C.1    Wolf, E.2    Hanhoff, N.3
  • 85
    • 58149170172 scopus 로고    scopus 로고
    • Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts)
    • Seng R, Goujard C, Desquilbet L, et al. Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts). J Acquir Immune Defic Syndr 2008;49(3):251-8
    • (2008) J Acquir Immune Defic Syndr , vol.49 , Issue.3 , pp. 251-258
    • Seng, R.1    Goujard, C.2    Desquilbet, L.3
  • 86
    • 34147166153 scopus 로고    scopus 로고
    • Effect of transient antiretroviral treatment during acute HIV infection: Comparison of the Quest trial results with CASCADE natural history study
    • Lampe FC, Porter K, Kaldor J, et al. Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antivir Ther 2007;12(2): 189-93
    • (2007) Antivir Ther , vol.12 , Issue.2 , pp. 189-193
    • Lampe, F.C.1    Porter, K.2    Kaldor, J.3
  • 87
    • 43349083498 scopus 로고    scopus 로고
    • Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection
    • Fox J, Scriba TJ, Robinson N, et al. Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. Clin Exp Immunol 2008;152(3):532-7
    • (2008) Clin Exp Immunol , vol.152 , Issue.3 , pp. 532-537
    • Fox, J.1    Scriba, T.J.2    Robinson, N.3
  • 88
    • 57349121049 scopus 로고    scopus 로고
    • The effect of antiretroviral treatment of different durations in primary HIV infection
    • Pantazis N, Touloumi G, Vanhems P, et al. The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS 2008;22(18):2441-50
    • (2008) AIDS , vol.22 , Issue.18 , pp. 2441-2450
    • Pantazis, N.1    Touloumi, G.2    Vanhems, P.3
  • 89
    • 84866130614 scopus 로고    scopus 로고
    • Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion
    • Lodi S, Meyer L, Kelleher AD, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012;172(16):1252-5
    • (2012) Arch Intern Med , vol.172 , Issue.16 , pp. 1252-1255
    • Lodi, S.1    Meyer, L.2    Kelleher, A.D.3
  • 90
    • 84865717158 scopus 로고    scopus 로고
    • HIV-1 control after transient antiretroviral treatment initiated in primary infection: Role of patient characteristics and effect of therapy
    • Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 2012;17(6):1001-9
    • (2012) Antivir Ther , vol.17 , Issue.6 , pp. 1001-1009
    • Goujard, C.1    Girault, I.2    Rouzioux, C.3
  • 91
    • 84858958596 scopus 로고    scopus 로고
    • No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: The randomized Primo-SHM trial
    • Grijsen ML, Steingrover R, Wit FW, et al. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med 2012;9(3):e1001196
    • (2012) PLoS Med , vol.9 , Issue.3
    • Grijsen, M.L.1    Steingrover, R.2    Wit, F.W.3
  • 92
    • 84555189233 scopus 로고    scopus 로고
    • The setpoint study (ACTG A5217): Effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals
    • Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 2012;205(1):87-96
    • (2012) J Infect Dis , vol.205 , Issue.1 , pp. 87-96
    • Hogan, C.M.1    Degruttola, V.2    Sun, X.3
  • 93
    • 84867566962 scopus 로고    scopus 로고
    • Temporary antiretroviral treatment during primary HIV-1 infection has a positive impact on health-related quality of life: Data from the Primo-SHM cohort study
    • Grijsen M, Koster G, van VM, et al. Temporary antiretroviral treatment during primary HIV-1 infection has a positive impact on health-related quality of life: data from the Primo-SHM cohort study. HIV Med 2012;13(10):630-5
    • (2012) HIV Med , vol.13 , Issue.10 , pp. 630-635
    • Grijsen, M.1    Koster, G.2    Van, V.M.3
  • 94
    • 84872436943 scopus 로고    scopus 로고
    • Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy
    • Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013;368(3):218-30
    • (2013) N Engl J Med , vol.368 , Issue.3 , pp. 218-230
    • Le, T.1    Wright, E.J.2    Smith, D.M.3
  • 95
    • 84884405076 scopus 로고    scopus 로고
    • The incidence of AIDS-defining illnesses at a current CD4 count 200 cells/mL in the post-combination antiretroviral therapy era
    • Mocroft A, Furrer HJ, Miro JM, et al. The incidence of AIDS-defining illnesses at a current CD4 count 200 cells/mL in the post-combination antiretroviral therapy era. Clin Infect Dis 2013;57(7):1038-47
    • (2013) Clin Infect Dis , vol.57 , Issue.7 , pp. 1038-1047
    • Mocroft, A.1    Furrer, H.J.2    Miro, J.M.3
  • 96
    • 27444433627 scopus 로고    scopus 로고
    • Structured treatment interruptions in primary HIV-1 infection: The ANRS 100 PRIMSTOP trial
    • Hoen B, Fournier I, Lacabaratz C, et al. Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial. J Acquir Immune Defic Syndr 2005;40(3):307-16
    • (2005) J Acquir Immune Defic Syndr , vol.40 , Issue.3 , pp. 307-316
    • Hoen, B.1    Fournier, I.2    Lacabaratz, C.3
  • 97
    • 84866735012 scopus 로고    scopus 로고
    • Continuous versus intermittent treatment strategies during primary HIV-1 infection: The randomized ANRS INTERPRIM Trial
    • Goujard C, Emilie D, Roussillon C, et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial. AIDS 2012;26(15):1895-905
    • (2012) AIDS , vol.26 , Issue.15 , pp. 1895-1905
    • Goujard, C.1    Emilie, D.2    Roussillon, C.3
  • 98
    • 0035958765 scopus 로고    scopus 로고
    • Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: Results from the Primoferon A (ANRS 086) Study
    • Emilie D, Burgard M, Lascoux-Combe C, et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 2001;15(11): 1435-7
    • (2001) AIDS , vol.15 , Issue.11 , pp. 1435-1437
    • Emilie, D.1    Burgard, M.2    Lascoux-Combe, C.3
  • 99
    • 0036139572 scopus 로고    scopus 로고
    • Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection
    • Dybul M, Hidalgo B, Chun TW, et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis 2002;185(1): 61-8
    • (2002) J Infect Dis , vol.185 , Issue.1 , pp. 61-68
    • Dybul, M.1    Hidalgo, B.2    Chun, T.W.3
  • 100
    • 70349768299 scopus 로고    scopus 로고
    • Antiretroviral therapy in acute and recent HIV infection: A prospective multicenter stratified trial of intentionally interrupted treatment
    • Volberding P, Demeter L, Bosch RJ, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 2009;23(15):1987-95
    • (2009) AIDS , vol.23 , Issue.15 , pp. 1987-1995
    • Volberding, P.1    Demeter, L.2    Bosch, R.J.3
  • 101
    • 0034085321 scopus 로고    scopus 로고
    • Effects of hydroxyurea on T cell count changes during primary HIV infection
    • Ravot E, Tambussi G, Jessen H, et al. Effects of hydroxyurea on T cell count changes during primary HIV infection. AIDS 2000;14(5):619-22
    • (2000) AIDS , vol.14 , Issue.5 , pp. 619-622
    • Ravot, E.1    Tambussi, G.2    Jessen, H.3
  • 102
    • 0036192919 scopus 로고    scopus 로고
    • Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy
    • Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109(5):681-8
    • (2002) J Clin Invest , vol.109 , Issue.5 , pp. 681-688
    • Rizzardi, G.P.1    Harari, A.2    Capiluppi, B.3
  • 103
    • 77950936860 scopus 로고    scopus 로고
    • The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection
    • Markowitz M, Vaida F, Hare CB, et al. The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis 2010; 201(9):1298-302
    • (2010) J Infect Dis , vol.201 , Issue.9 , pp. 1298-1302
    • Markowitz, M.1    Vaida, F.2    Hare, C.B.3
  • 105
    • 38649136321 scopus 로고    scopus 로고
    • Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection
    • Lewin SR, Murray JM, Solomon A, et al. Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. J Acquir Immune Defic Syndr 2008;47(2): 140-7
    • (2008) J Acquir Immune Defic Syndr , vol.47 , Issue.2 , pp. 140-147
    • Lewin, S.R.1    Murray, J.M.2    Solomon, A.3
  • 106
    • 84887028999 scopus 로고    scopus 로고
    • Absence of detectable hiv-1 viremia after treatment cessation in an infant
    • Persaud D, Gay H, Ziemniak C, et al. Absence of detectable hiv-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369(19):1828-35
    • (2013) N Engl J Med , vol.369 , Issue.19 , pp. 1828-1835
    • Persaud, D.1    Gay, H.2    Ziemniak, C.3
  • 107
    • 84875985311 scopus 로고    scopus 로고
    • Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study
    • Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013;9(3):e1003211
    • (2013) PLoS Pathog , vol.9 , Issue.3
    • Saez-Cirion, A.1    Bacchus, C.2    Hocqueloux, L.3
  • 109
    • 84901502098 scopus 로고    scopus 로고
    • A randomized open-label study of three-versus five-drug combination antiretroviral therapy in newly hiv-1 infected individuals
    • Epub ahead of print
    • Markowitz M, Evering TH, Garmon D, et al. A randomized open-label study of three-versus five-drug combination antiretroviral therapy in newly hiv-1 infected individuals. J Acquir Immune Defic Syndr 2014. [Epub ahead of print]
    • (2014) J Acquir Immune Defic Syndr
    • Markowitz, M.1    Evering, T.H.2    Garmon, D.3
  • 110
    • 79959465186 scopus 로고    scopus 로고
    • Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA
    • Gianella S, von Wyl V, Fischer M, et al. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther 2011;16(4):535-45
    • (2011) Antivir Ther , vol.16 , Issue.4 , pp. 535-545
    • Gianella, S.1    Von Wyl, V.2    Fischer, M.3
  • 112
    • 84896717701 scopus 로고    scopus 로고
    • Are infants unique in their ability to be "functionally cured" of HIV-1?
    • Tobin NH, Aldrovandi GM. Are infants unique in their ability to be "functionally cured" of HIV-1? Curr HIV/AIDS Rep 2014;11(1):1-10
    • (2014) Curr HIV/AIDS Rep , vol.11 , Issue.1 , pp. 1-10
    • Tobin, N.H.1    Aldrovandi, G.M.2
  • 114
    • 84864131448 scopus 로고    scopus 로고
    • Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel
    • Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308(4):387-402
    • (2012) JAMA , vol.308 , Issue.4 , pp. 387-402
    • Thompson, M.A.1    Aberg, J.A.2    Hoy, J.F.3
  • 116
    • 84902499814 scopus 로고    scopus 로고
    • Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2013)
    • Panel de expertos de Gesida y Plan Nacional sobre el SIDA; In press
    • Panel de expertos de Gesida y Plan Nacional sobre el SIDA. Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2013). Enferm Infecc Microbiol Clin 2013;In press
    • (2013) Enferm Infecc Microbiol Clin
  • 117
    • 84907817074 scopus 로고    scopus 로고
    • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012
    • Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012;13(Suppl 2):1-85
    • (2012) HIV Med , vol.13 , Issue.SUPPL. 2 , pp. 1-85
    • Williams, I.1    Churchill, D.2    Anderson, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.